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IL-1, originally called lymphocyte activating factor, is a cytokine synthesized and
secreted by macrophages in response to stimulationby endotoxin and certain other
agents (reviewed in reference 1). IL-1 can also be produced by other cell types (1,
2), including vascular endothelial cells (3, 4), and is thought to play a central role
in host defenses by virtue of its ability to augment the replication of activated T
cells and to mediate the humoral and cellular events ofinflammation. Because the
genes for IL-la and IL-1ß have beencloned and expressed (5-7), rIL-1 is now avail-
able in sufficient quantity to investigate its abilitytoaugment host-immunedefense
mechanisms in vitro and in vivo, including those that might protect against neo-
plastic diseases. The claim that IL-1 has antitumor action isbased, however, on the
demonstrations that it is directly cytostatic for certain tumor cells in vitro (8) and
is cytotoxic for others (9, 10). More recently, it was demonstrated (11) that IL-1 can
cause complete regression of a small murine fibrosarcoma when injected directly
into the tumor, but only partial regression when injected intravenously. There re-
mains a need to determine, therefore, whether IL-1 has the capacity to cause tumor
regression indirectly through its ability to systemically augment host antitumor-
immune defense mechanisms.
The purpose ofthis paperis to showthat intraperitoneal injection ofhuman rIL-1
can cause complete regression ofa relatively large, immunogenic murine sarcoma
growing subcutaneously, byaugmenting the generation or expression ofan already
ongoing, T cell-mediated, concomitant immune response.
Materials and Methods
Mice.
￿
A/J, DBA/2, AB6F1(A x C57BL/6),andB6D2F1(C57BL/6 x DBA/2) mice(10-12
wkofage) wereobtainedfromtheTrudeau InstituteAnimal Breeding Facility, SaranacLake,
NY. The mice were known to befree ofviral pathogens according to the resultsoftests rou-
tinely performedby theDiagnostic Testing ServiceofMicrobiological Associates, Bethesda,
MD. The average weight of the mice was -20 g when they were used in experiments.
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Tumors.
￿
The SAl sarcoma and YAC-1 lymphoma (A/J), and L5178Y lymphoma and P815
mastocytoma (DBA/2) were passaged as ascites, harvested, cryopreserved, and prepared for
implantation as described previously (12, 13). The origins of these tumors were also described
previously (12, 13). For experiments, tumors were initiated intradermally in the belly region
by injecting 106 tumor cells in a volume of 0.05 ml of PBS. Tumor growth and regression
was monitored by measuring changes against time in the mean of two diameters measured
at right angles.
TCell-deficient (TXB)Mice.
￿
Tcell deficiency was achieved by thymectomy at 6 wk of age
followed 1 wk later by exposure to 1,000 rid ofy radiation delivered from a "'Cs source at
30 rid/min. Immediately after irradiation the mice were infused with 2 x 106 bone marrow
cells, and were used in experiments no sooner than 4 wk later.
Adoptive Immunization.
￿
Mice bearing the SAl sarcoma (14) and other tumors (15, 16) are
known to possess peak levels of T cell-mediated concomitant immunity on day 9 of tumor
growth. Spleen cells from such mice were used to passively transfer concomitant immunity
to TXB recipients bearing a smaller (6 d) tumor. The spleen cells were obtained by gently
pushing finely diced pieces ofspleen through a 60-mesh stainless screen into PBS containing
1% FCS. The resultingcell suspension was triturated with a Pasteur pipette to break up clumps,
passed through surgical gauze to remove debris, washed in PBS, and resuspended in PBS
for intravenous infusion. Recipients received one spleen equivalent (1.8 x 108) of cells from
tumor-bearing donors, or two spleen equivalents (2 x 108) of cells from normal donors.
Depletionof T Cell Subsets.
￿
To selectively remove Thy-1.2', L3T4', or Ly-2.2` T cells, the
spleen cells were incubated for 30 min at 10°C at 5 x 10'/ml in the appropriate mAb solu-
tion, and then in a 1 :10 dilution ofrabbit serum at 37°C for 30 min. Monoclonal antiThy-
1.2, and anti-Ly-2 .2 were secreted by clone 30-H12 and clone TIB-150, respectively (Amer-
ican Type Culture Collection, Rockville, MD). Monoclonal anti-L3T4 was secreted by clone
GK-1.5 obtained from Dr. Frank Fitch, Department of Pathology, University of Chicago.
All hybridomas were grown to 5 x 105/ml in RPMI 1640 medium (Gibco Laboratories,
Grand Island, NY) containing 10% FCS and 100 U/ml each ofpenicillin and streptomycin.
The cultures were centrifuged and the supernatants (containing 10-20 gg of Ab/ml) were
dispensed and stored at -20°C until required. They were used at a 1 :5 dilution in RPMI
1640 medium.
Interleukin 1.
￿
The IL-1p used in these studies (derived from a clone designated DP516)
was produced in Escherichia coli from a plasmid containing the DNA sequence for the mature
1.7kD form of human IL-1(i (17). The soluble protein was purified to >96% purity from the
supernatant fluids of bacterial extracts by ion exchange and molecular sieving column chro-
matography. The rIL-1p differed from the native sequence IL-10 by the addition of threo-
nine and asparagine residues on the NH2-terminal end of the molecule before amino acids
117-269 of the IL-10 precursor molecule. DP516 had a specific activity comparable with that
of purified monocyte-derived IL-1(i (107 U/mg), as measured by the thymocyte proliferation
assay, and had low levels (<10 ng/mg protein) ofendotoxin (17). IL-1 was stored at 4°C, diluted
in PBS, and injected intraperitoneally in the doses indicated in Results.
Results
Several SmallDosesofIL-1 Are CapableofCausingCompleteRegression oftheSA1 Sarcoma.
It is known (14) that underlying host, T cell-mediated immunity to the SA1 sarcoma
is not generated until day 6 of tumor growth and peaks on day 9. Therefore, in the
first experiment we tested the effect of giving IL-1 intraperitoneally in a dose of 1
gg daily for 1, 2, 3, or 4 d beginning on day 6 of tumor growth. Fig. 1 shows that
1 gg of IL-1 daily for either 3 or 4 d resulted in complete regression of the tumor
in five offive mice, whereas 1 gg daily for 2 d resulted in complete tumor regression
in three of five mice. A single 1-ltg injection of IL-1 on day 6 o£ tumor growth failed
to cause regression of the tumor in any mice, although the rate of tumor growth
temporarily decreased. In all cases, complete regression ofthe primary tumor resulted
in long-term host survival.NORTH ET AL.
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FIGURE 1.
￿
Effect on the SA1 sarcoma growing subcutaneously in AB6F1 mice of injecting 1
ug ofIL-1 intraperitoneally on day6, days 6 and 7, days 6-8, or days 6-9 oftumorgrowth. Three
injections ofIL-1 were needed to reproducibly cause complete regression ofthetumorin all mice.
Means of five mice per group.
It was also found that 1 ug of IL-1 injected daily between days 6 and 10 of tumor
growth resulted in complete regression of the SA1 sarcoma in syngeneic A/J mice.
Therefore, since there was no difference between the results obtained with A/J and
AB6F1 mice, the latter mice were used in all subsequent experiments, because they
were more plentiful and less expensive.
Effect of a Single Dose of IL-l.
￿
The possibility that a single large dose of IL-1 was
just as therapeutic as several small doses was next investigated by determining the
effect of giving a single 10-wg dose intraperitoneally on day 6 or 9 of tumor growth.
As seen in Fig. 2, a 10-Itg dose given on day 9 of tumor growth had no significant
therapeutic effect, whereas the same dose given on day 6 caused complete tumor
regression in twomice and partialregression in three. Therefore, small doses ofIL-1
between days 6 and 9 of tumor growth were more therapeutic than a large dose on
day 6or9.
In the same vein, Fig. 3 shows that multiple large doses of IL-1 were no more
therapeutic than multiple smalldoses givenduring the same period oftumorgrowth.
Thus, giving 10 jig dailybetween days 6 and 10 of tumor growth was no more thera-
peutic than giving 5, 1, or 0.5 Ng on the same days, in that the time of onset and
the rate of tumor regression were the same in all cases. However, injections of 0.1
ttg daily were without therapeutic effect (result not shown).
IL-1 Was Less Therapeutic Against Two Other Tumors.
￿
The foregoing results show2034
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that IL-1 given in relatively small doses intraperitoneally is capable of reproducibly
causing complete regression of an established SAl sarcoma growingsubcutaneously.
It was important to determine next whether IL-1 was capable of causing regression
of other immunogenic murine tumors. Therefore, the effect of multiple injections
ofIL-1 on growth of the L5178Y lymphoma andP815 mastocytomawas determined.
Fig. 4 shows that 10 gg of IL-1 daily for 5 d beginning on day 6 of tumor growth
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￿
Evidence that a single large
dose of IL-1 is not as therapeutic as sev-
eral much smaller doses. A single 10-ug
dose ofIL-1 givenon day 6 or 9 of tumor
growth was less therapeutic than 1 gg
given on days 6-8, as shown in Fig. 1.
Giving 10 ttgof IL-1 on day 6 caused com-
plete regression ofthetumorin two mice
and its partial regression in three. How-
ever, giving 10 gg of IL-1 on day 9 failed
to result in asignificant therapeutic effect.
Means of five mice per group.
FIGURE 3.
￿
Evidence that sub-
stantially increasing the dose of
IL-1 givendaily for5 ddid not
result in earlier onset of tumor
regression. Injection of 10 gg of
IL-1 on days 6-10 of tumor
growth wasno moretherapeutic
than 5, 1, or 0.05 gg given on
the same days. Means of five
mice per group.NORTH ET AL.
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Evidence that IL-1
y
￿
wasless therapeutic against the o
L5178Ylymphoma than against
the SA1 sarcoma. Injecting 1
gg of IL-1 on days 6-10 of
growth ofthe L5178Y failed to
cause its regression. However,
injecting 10 gg of IL-1 on the
same days caused its complete
regression in all mice, and
resulted in long-termsurvival of
most mice. Means of five mice
per group.
resulted in complete regression of the L5178Y lymphoma in five of five mice, and
in long-term survival of three of five mice. In contrast, 1 gg of IL-1 daily during
the same period had no significant effect on tumor growth or on host survival.
IL-1 was less therapeutic against the P815 mastocytoma (Fig. 5), in that not even
10 gg daily for 5 d caused complete regression of this tumor, although it did cause
a temporary decrease in the rate of tumor growth, and an increase in host survival
time. Injecting 1 gg daily was less therapeutic.
IL-Y Is not Therapeutic if Given Too Early During Tumor Growth.
￿
The rationale for
giving IL-1 between days 6 and 9 oftumor growth was based on the knowledge that
underlying host, T cell-mediated immunity to the SAl sarcoma (14) and to other
tumors (15, 16) is not generated until day 6 of tumor growth and peaks on about
day 9. If IL-1 requires this ongoing underlying antitumor immune response to be
therapeutic, then, IL-1 should not be therapeutic if given during the first few days
of tumor growth, before the generation of concomitant immunity has commenced.
Fig. 6 shows theresult ofan experiment that compared the therapeutic effect of giving
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FIGURE 5. Evidence that the
P815 mastocytoma was theleast
responsive to IL-1 therapy of the
three tumors tested. A dose of
10 jig of IL-1 on days 6-10 of
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tumor growth caused only a
temporary halt in tumor pro-
gression, although host survival
time was significantly increased.
Means of five mice per group.
IL-1 on days 1-3 of tumor growth with its therapeutic effect when given on days
6-8. Whereas injection of 10 ug of IL-1 on day 6-8 of tumor growth resulted in
complete regression of thetumor in allmice, injectingthe same relatively largedose
on days 1-3 had no effect on tumor growth .
IL-1-induced Tumor Regression Is Dependent on Underlying T Cell-mediated Immunity.
The foregoing results suggest that IL-1 treatment cannot exert an antitumor effect
until the tumor is large enough to evoke the generation of host concomitant immu-
nity. If so, then IL-1 should not be capable of causing regression of the SAl sarcoma
growing in TXB mice. As shown in Fig. 7, intravenous injection of 1 Fig of IL-1
on day6-9 oftumor growth caused complete regression ofthe SAl in immunocompe-
tent mice, but failed to cause regression of the tumor growing in TXB mice.
Direct evidence that the therapeutic action of IL-1 is dependent on T cell-medi-
ated immunity came from experiments that determined whether IL-1 is capable of140
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￿
Evidence that IL-1 was not therapeutic if given too early during growth of the SAl
sarcoma . A dose of 10 Itg of IL-1 given on days 1-3 of tumorgrowth gave no therapeutic effect,
whereas the same dose given on days 6-8 caused complete tumor regression in all mice . Means
of five mice per group.
causing regression ofatumor in TXB mice, provided they are infused with T cells
from immunocompetent tumor-bearingdonors . In the first experiment TXB mice
bearing either a 6-d SAl sarcoma, or a 6-d syngeneic YAC-1 lymphoma, were in-
fused with one organ equivalent (1 .8 x 10s) of spleen cells from donor mice bearing
SA-1
tp9 IL-1 IV
NORTH ET AL.
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FIGURE 7 . Evidence that the
therapeuticeffect ofIL-1 against
theSAlsarcomaisT cell depen-
dent . IL-1 in a dose of 1 kg
given intravenously on days 6-9
of tumor growth caused com-
plete regression ofthe tumor in
immunocompetent mice (left),
but not in TXB mice (right) .
Means of five mice per group.2038
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FIGURE 8.
￿
Restoration oftheability ofTXBmice to cause regression oftheirtumorin response
to IL-1 therapy by infusing them with spleen cells from donor mice bearinga 9-d tumor. SAl-
bearingTXBrecipients (deft) were able tocauseregression oftheirtumorin response to injection
of 1 jig of IL-1 on days 6-8, provided they were infused on day 6 with spleen cells from SA1-
bearingdonors (SAl-IMM + IL-1), but not with spleen cells from YAC-1 lymphoma-bearing
donors (YAC-IMM + IL-1). YAC-1 lymphoma-bearing TXB recipients (right) failed to cause
regression of theirtumors in response to IL-1 therapy ifthey were infused with spleen cells from
SAl-bearing donors (SAl-IMM + IL-1). However, spleen cells from YAC-1 lymphoma-bearing
donors were capable of causing regression of this tumor without (YAC-IMM), as well as with
IL-1 (YAC-IMM + IL-1). Means of five mice per group.
one or the other of these tumors, and injected on day 6-9 with 1 hg of IL-1. It can
be seen in Fig. 8, that combined treatment with immune spleen cells and IL-1 resulted
in complete regression of the SA1 sarcoma in all mice. In contrast, treatment with
IL-1 alone, or in combination with normal spleen cells, failed to give a significant
therapeutic effect (Fig. 9). Moreover, in order for tumor regression to occur, it was
necessary to infuse spleen cells from donors bearing thehomologous tumor, in that
IL-1 caused regression of the SAI sarcoma in TXB mice infused with spleen cells
from SAI-bearingdonors, butnot in TXB mice infusedwith spleen cellsfrom YAC-
1-bearingdonors (Fig. 8). However, in this experiment infusion of spleen cellsfrom
YAC-1 lymphoma-bearing donors resulted in regression of the YAC-1 lymphoma
in TXB recipients without the need for IL-1 treatment. This undoubtedly was be-
cause the YAC-1 lymphoma, being highly immunogenic, evoked the generation of
high levels of immunity in the donors. This immunity was sufficient to cause regres-
sion ofthedonors tumorat thetime that spleen cellswere harvestedforpassivetransfer.
Regardless of this, it is apparent from results with the SA1 that injection of IL-1
served to convert a subtherapeutic level of adoptive anti-SAI immunity to a thera-
peutic level.E
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FIGURE 9.
￿
Additional controls for showing that normal spleen cells did not restorethe ability
ofTXBmice to causeregression ofthe SAl sarcoma (left) or YAC-1lymphoma (sight)in response
to IL-1 therapy (IL-1 + NORM). Means of five mice per group.
Evidence that the spleen cells from SA1-bearing donors that imparted to TXB
recipients the abilitytocauseregressionoftheSA1 sarcoma inresponse toIL-1 therapy
are T cells is provided in Fig. 10. It can be seen that IL-1 failed to cause regression
ofthe SA1 sarcoma in TXB mice infused with donor spleen cells treated with anti-
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FIGURE 10.
￿
Evidence that the
spleen cellsfrom immunocom-
petent tumor-bearing donors
that restore the ability ofTXB
recipients to cause regression
oftheirtumorin response to IL-
1 therapy were Ly-2' and
L3T4' T cells. Infusion of do-
nor spleen cells on day 6 of
tumorgrowthenabledTXBre-
cipients to cause regression of
their tumor in response to in-
jection of 1 gg of IL-1 on day
6-10 (IMM + IL-1), but notif
the spleen cells were treated
with antiThy-1.2 antibody (IL-
1 + aThy-1.2 IMM), anti-
L3T4 antibody (IL-1 +
aL3T4IMM), or anti-Ly-2 an-
tibody (IL-1 + aLy-2 IMM)
andcomplement. Meansoffive
mice per group.
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Thy-1.2 antibody and complement, anti-Ly-2.2 antibody and complement, or anti-
L3T4 antibody and complement. Therefore, both L3T4+ and Ly-2 + tumor-
sensitized T cells were required for the therapeutic action of IL-1.
Discussion
The results of this study show that intraperitoneal injection of human rIL-1(3 can
causeregression of the immunogenic SAI sarcomaand L5178Y lymphoma growing
subcutaneously in syngeneicor semisyngeneic mice. The SAI sarcoma wasthe more
responsive of these two tumors to IL-1 therapy and underwent complete regression
after injection of 0.5 gg of IL-1 daily between days 6 and 10 of tumor growth. The
L5178Y lymphoma failed to undergo regression in response to injection of 1 gg of
IL-1 on the same days, but did so after injections of 10 wg. On the other hand, the
P815 mastocytoma did not undergo complete regression, even in response to injec-
tions of the 10-ug dose, although host survival was significantly prolonged. There-
fore, although it remains to be determined whether higher doses of IL-1 can cause
regression of the P815 mastocytoma, the results obtained thus far leave no doubt
that some immunogenictumors will proveto be much more susceptible to IL-1 therapy
than others, and that nonimmunogenic tumors are likely to prove quite refractory.
Evidence that IL-1 therapy depends on host antitumor immunity is supplied by
results showing that IL-1 failed to cause regression of the SA1 sarcoma growing in
TXB mice that were incapable of generating a T cell-mediated concomitant im-
mune response. More direct evidence is seen in the additional demonstration that
IL-1 therapy could cause regression of the SAl sarcoma growing in TXB mice,
provided these mice were first infused with splenic T cells from immunocompetent
donor-mice bearing a 9-d SA1 sarcoma. On the other hand, IL-1 failed to cause
regression of the SA1 sarcoma in TXB mice that were infused with normal splenic
T cells, or with splenic T cells from donor mice bearing a different immunogenic
tumor. Furthermore, theT cells that imparted to TXB recipients the ability to reject
the SAI sarcomain response to IL-1 therapywere susceptible to anti-Ly-2 antibody
and complement, and anti-L3T4 antibody and complement.
It is known that concomitant immunity to the SA1 sarcoma(14) and other tumors
(15, 16), as measured by thepresence in the host ofT cells capableof passively trans-
ferringimmunity to appropriate recipients, is first evident on day 6 oftumorgrowth,
peaks on day 9, and progressively decays thereafter. This was the reason why IL-1
was given between days 6 and 9 of tumor growth. Indeed, because IL-1 was ther-
apeuticwhen givendailybetween days 6and 9 of tumorgrowth, butnot when given
betweendays 0 and 3, it can be suggested that the therapeutic action ofthe molecule
requires that the host concomitant immune response be already induced and on-
going. This would be in keeping with the interpretation (18) that IL-1 stimulates
replication of T cells only after they have been activated by mitogens or specific an-
tigens. Results relevant to the findings presented here were recently published by
Mannie et al. (19), who showed that rat T cells sensitized to myelin basic protein
and capable of causing allergic encephalomyelitis in recipient rats can be expanded
in number by incubating them with IL-1 in vitro, but only in the presence of myelin
basic protein. Thus, although the role of IL-1 in T cell replication remains a con-
troversial topic (2, 18), it is reasonable to suggest on the basis ofthe results presented
that IL-1 causes regression of the SA1 sarcoma by stimulating an increase in theNORTH ET AL.
￿
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production of SAl-sensitized T cells, thereby converting a subtherapeutic number
of sensitized T cells to a therapeutic number. A study still in progress (North, Dye,
and Dunn) shows that SA1-bearing mice treated with IL-1 between days 6 and 9
of tumor growth contain more SA1-sensitized T cells than control tumor bearers.
This is evidenced by the finding that it required far fewer spleen cells from these
mice on day 9 oftumor growth than from control tumor bearers to cause regression
of a 5-d tumor in irradiated recipient mice. Whether this involves an increase in
the replication of T cells already in cycle, or the recruitment into cycle of T cells
that are suboptimally activated is not yet known, but is amenable to analysis. Also
not known at this time is why a single 10-lig dose of IL-1 given on day 6 or 9 of
tumor growth is not as therapeutic as a much smaller dose given on days 6-9.
The resultsof this studyas awhole are notin keepingwith the view that the ther-
apeutic action of IL-1 is based on its capacities to directly inhibit the growth of, or
to destroy, tumor cells in vivo. IL-1 given intraperitoneally did not cause a tumor
hemorrhagic reaction of the type that occurs rapidly after intravenous injection of
TNF (20). Instead, the antitumoreffect of IL-1 was not obvious until long after it
would have been expected to have disappeared from the circulation. Moreover, the
appearance of the tumor during IL-1-induced regression was similar to its appear-
ance while undergoing regression in response to adoptive T cell-mediated immu-
nity, as studied previously (21), in that the ring of living tumor tissue external to
the tumor's necrotic core lost its pink color and slowly resorbed. Therefore, the rele-
vance of the results presented here to descriptions of a direct cytostatic (8) or cyto-
toxic (9, 10) action of IL-1 for certain tumor cells in vitro is not obvious.
Exogenous IL-1, then, appearsto be an in vivo immunoaugmenting agent capable
of causing the regression of tumors of sufficient immunogenicity by augmenting an
already ongoing host concomitant immune response. The results presented serve
to illustrate the importance of having a knowledge of the magnitude and kinetics
of generation ofthis host immune response, before attempts are made to causetumor
regression with IL-1, or othersuspected immunomodulators. It was shown recently,
in this regard, that tumor regression caused by administration of exogenous TNF
(20), or: by induction of endogenous TNF by endotoxin (21), is dependent on the
possession by the host of an adequate level of concomitant antitumor immunity.
Summary
Intraperitoneal injection of human rIL-1 in a dose of 0.5 wg daily for 5 d, or 1
wg daily for 3 d, was capable of causing complete regression of immunogenic SAl
sarcoma growing subcutaneously in syngeneic or semisyngeneic mice. Higher doses
of IL-1 were not more therapeutic against the SA1 sarcoma, but needed to be given
to cause complete regression of the immunogenic L5178Y lymphoma. On the other
hand, the P815 mastocytoma was much less responsive to IL-1 therapy, in that it
failed to undergocomplete regression in response to doses of IL-1 capable ofcausing
regression of the L5178Y lymphoma. IL-1 caused regression of the SA1 sarcoma
when given on days 6-8 of tumor growth, but not when given on days 1-3. This
refractoriness of a small tumor to IL-1 therapy suggests that the antitumor action
of IL-1 is based on an underlying host-immune response that is not generated until
after day 3 of tumor growth. Direct evidence for the participation ofhost immunity
in IL-1-induced tumor regression was supplied by results showing that IL-1 was not2042
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therapeutic against the SAI sarcoma growing in T cell-deficient (TXB) mice, unless
these mice were first infused with Ly-2 + and L3T4+ T cells from donor mice
bearing an established SAI sarcoma. In contrast, normal T cells, or T cells from
donor mice bearing a YAC-1 lymphoma, failed to provide TXB recipients with the
ability to cause regression oftheir SA-1 sarcoma in response to IL-1 treatment. The
results are in keeping with the interpretation that exogenous IL-1, by augmenting
the production of tumor-sensitized T cells, converts a subtherapeutic level of host
immunity to a therapeutic level. The results suggest, in addition, that IL-1 only stimu-
lates the replication of T cells that are already engaged in the antitumor immune
response.
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